Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Stoke Therapeutics (NASDAQ:STOK) and maintained a $22 price target.

April 11, 2024 | 10:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham maintains a Buy rating and a $22 price target on Stoke Therapeutics.
The reiteration of a Buy rating and maintenance of a $22 price target by a reputable analyst like Joseph Stringer from Needham is likely to instill confidence among investors and could positively influence Stoke Therapeutics' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100